Monthly Archives: November 2008

Join the Journal of Commercial Biotechnology discussion group on LinkedIn:

This group focuses on the biotech industry. The audience and focus are the same as for the Journal of Commercial Biotechnology: Professionals who need to enhance their knowledge of biotechnology business strategy and management, improve and advance their product development or want to keep up-to-date with the current issues and industry trends.

Topics include:

  • Corporate strategy
  • Financing
  • Bioethics
  • Public and investor relations
  • Market analysis
  • Legal and regulatory issues

While you’re at it, join my network too.

Those who have been following this blog for long enough probably know what it means when posting slows down — it means that I’ve got a new project in the works. I’m currently working on a new online platform for biotechnology education. It should be ready for beta testing by December first, and formally launch early in 2009.

Let me know if you might be interested in helping beta test this online education platform. And while you’re waiting for more posts, check out some of the fantastic guest content.

Courtesy of

Drug Patent Expirations in November 2008

*Drugs may be covered by multiple patents

Tradename Applicant Generic Name Patent Number Patent Expiration
ALKERAN Glaxosmithkline melphalan hydrochloride 4,997,651 Nov 18, 2008
BREVIBLOC Baxter Hlthcare Corp esmolol hydrochloride 5,017,609 Nov 21, 2008
BUSPAR Bristol Myers Squibb buspirone hydrochloride 5,015,646 Nov 14, 2008
COVERA-HS Gd Searle Llc verapamil hydrochloride 5,030,456 Nov 7, 2008
DYNACIRC CR Smithkline Beecham isradipine 5,030,456 Nov 7, 2008
NEUROLITE Lantheus Medcl technetium tc-99m bicisate kit 5,279,811 Nov 23, 2008
NEURONTIN Parke Davis gabapentin 4,894,476 Nov 2, 2008
NEURONTIN Pfizer Pharms gabapentin 4,894,476 Nov 2, 2008
NUVIGIL Cephalon armodafinil 4,927,855 Nov 22, 2008
PRELAY Sankyo troglitazone 4,572,912 Nov 9, 2008
REZULIN Pfizer Pharms troglitazone 4,572,912 Nov 9, 2008

Courtesy of